TP53截断突变作为局部晚期口腔鳞癌诱导化疗预测性生物标志物的探讨

doi:10.19438/j.cjoms.2018.04.006

中国口腔颌面外科杂志 ›› 2018, Vol. 16 ›› Issue (4): 322-327.doi: 10.19438/j.cjoms.2018.04.006

TP53截断突变作为局部晚期口腔鳞癌诱导化疗预测性生物标志物的探讨

付永¹, 马捷¹, 刘莹¹, 谈亦然¹, 琚梧桐¹, 孙文文¹, 赵铜超¹, 王旻¹, 王丽珍², 李江², 张陈平¹, 张志愿¹, 钟来平¹

1.上海交通大学医学院附属第九人民医院·口腔医学院口腔颌面-头颈肿瘤科,
2.口腔病理科, 国家口腔疾病临床研究中心,上海市口腔医学重点实验室,上海市口腔医学研究所

收稿日期:2018-04-18 修回日期:2018-07-09 出版日期:2018-07-20 发布日期:2018-08-09
通讯作者: 钟来平,E-mail：zhonglaiping@163.com
作者简介:付永（1990-）,男,硕士研究生,E-mail：fy114@foxmail.com
基金资助:
国家自然科学基金（81472519,81672660）; 上海市教育委员会曙光计划（17SG18）

TP53 truncating mutation as a predictive biomarker for induction chemotherapy in patients with locally advanced oral squamous cell carcinoma

FU Yong¹, MA Jie¹, LIU Ying¹, TAN Yi-ran¹, JU Wu-tong¹, SUN Wen-wen¹, ZHAO Tong-chao¹, WANG Min¹, WANG Li-zhen², LI Jiang², ZHANG Chen-ping¹, ZHANG Zhi-yuan¹, ZHONG Lai-ping¹

1.Department of Oromaxillofacial Head and Neck Oncology,
2.Department of Oral Pathology, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine; National Clinical Research Center For Oral Diseases; Shanghai Key Laboratory of Stomatology & Shanghai Research Institute of Stomatology. Shanghai 200011, China;

Received:2018-04-18 Revised:2018-07-09 Online:2018-07-20 Published:2018-08-09

摘要/Abstract

摘要： 目的:检测TP53在局部晚期口腔鳞癌患者中的突变情况,探讨TP53截断突变能否作为生物标志物筛选诱导化疗获益患者。方法:选择2008—2014年收治的101例局部晚期口腔鳞癌患者,收集患者临床病理信息、肿瘤及正常对照新鲜冷冻或石蜡包埋样本。采用Ion Torrent PGM平台进行高通量测序,通过生物信息学软件进行突变识别及注释,采用SPSS 23.0软件包进行统计学分析。结果:101例患者中,男74例,女27例,中位年龄59岁,中位随访时间为34.9个月。平均测序深度肿瘤样本为2366乘,正常对照样本为2225乘。在73例患者中,检测出102个TP53非同义突变（等位基因频率≥3%）。与42例手术组口腔鳞癌患者相比,诱导化疗组（59例）无远处转移生存率较好（P=0.090）,但总生存率无显著差异。亚组分析显示,带有TP53截断突变的患者可以从诱导化疗中得到无远处转移生存获益（P=0.038）。结论:本研究未发现诱导化疗能整体提高局部晚期口腔鳞癌患者的生存期,但TP53截断突变可作为潜在的预测性生物标志物,筛选诱导化疗无远处转移生存获益的患者。

关键词: 口腔鳞状细胞癌, TP53截断突变, 无远处转移生存, 生物标志物, 诱导化疗

Abstract: PURPOSE:To test the status of TP53 mutations in patients with locally advanced oral squamous cell carcinoma (OSCC) and investigate whether or not TP53 truncating mutation could be used as a predictive biomarker to screen patients who would benefit from induction chemotherapy. METHODS: One hundred and one patients with locally advanced OSCC treated in our hospital from 2008 to 2014 were included in this study. Their clinicopathologic information, frozen or formalin-fixed, paraffin-embedded samples of tumor and matched normal samples were collected. Using Ion PGM system, all samples were sequenced with high-throughput technology. Bioinformatics software was used to analyze and interpret the variants. SPSS 23.0 software package was used for statistical analysis. RESULTS: Among 101 patients, there were 74 men and 27 women with a median age of 59 years. The median follow-up time was 34.9 months. There were 102 TP53 non-synonymous mutations (allele frequency ≥3%) in 73 OSCC patients, with an average sequencing depth of 2366-fold in the tumor samples and 2225-fold in the matched normal samples. Compared with 42 patients who did not receive induction chemotherapy, 59 patients who received induction chemotherapy had a seemingly better distant metastasis free survival (P=0.090) while no significant difference in overall survival. Subgroup analysis showed that patients with TP53 truncating mutations could benefit from induction chemotherapy in distant metastasis free survival (P=0.038). CONCLUSIONS: Our study does not find that the patients with locally advanced OSCC could benefit from induction chemotherapy in overall survival, but TP53 truncating mutation could be used as a candidate of predictive biomarker to screen patients who would benefit from induction chemotherapy in distant metastasis free survival.

Key words: Oral squamous cell carcinoma, TP53 truncating mutation, Distant metastasis free survival, Biomarker, Induction chemotherapy

中图分类号:

R739.8

付永, 马捷, 刘莹, 谈亦然, 琚梧桐, 孙文文, 赵铜超, 王旻, 王丽珍, 李江, 张陈平, 张志愿, 钟来平. TP53截断突变作为局部晚期口腔鳞癌诱导化疗预测性生物标志物的探讨[J]. 中国口腔颌面外科杂志, 2018, 16(4): 322-327.

FU Yong, MA Jie, LIU Ying, TAN Yi-ran, JU Wu-tong, SUN Wen-wen, ZHAO Tong-chao, WANG Min, WANG Li-zhen, LI Jiang, ZHANG Chen-ping, ZHANG Zhi-yuan, ZHONG Lai-ping. TP53 truncating mutation as a predictive biomarker for induction chemotherapy in patients with locally advanced oral squamous cell carcinoma[J]. China J Oral Maxillofac Surg, 2018, 16(4): 322-327.

参考文献

[1] Warnakulasuriya S.Global epidemiology of oral and oropharyngeal cancer[J]. Oral Oncol, 2009, 45(4-5): 309-316.
[2] Torre LA, Bray F, Siegel RL, et al.Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108.
[3] Gyawali B, Shimokata T, Honda K, et al.Chemotherapy in locally advanced head and neck squamous cell carcinoma[J]. Cancer Treat Rev, 2016, 44(1):10-16.
[4] Paccagnella A, Mastromauro C, D'Amanzo P, et al. Induction chemotherapy before chemoradiotherapy in locally advanced head and neck cancer: the future?[J]. Oncologist, 2010, 15(Suppl 3):8-12.
[5] Busch CJ, Tribius S, Schafhausen P, et al.The current role of systemic chemotherapy in the primary treatment of head and neck cancer[J]. Cancer Treat Rev, 2015, 41(3): 217-221.
[6] Haddad R, O'Neill A, Rabinowits G, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial[J]. Lancet Oncol, 2013, 14(3): 257-264.
[7] Zhong LP, Zhang CP, Ren GX, et al.Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma[J]. J Clin Oncol, 2013, 31(6): 744-751.
[8] Cohen EE, Karrison TG, Kocherginsky M, et al.Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer[J]. J Clin Oncol, 2014, 32(25): 2735-2743.
[9] Steels E, Paesmans M, Berghmans T, et al.Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis[J]. Eur Respir J, 2001, 18(4): 705-719.
[10] Weller M, Felsberg J, Hartmann C, et al.Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the german glioma network[J]. J Clin Oncol, 2009, 27(34): 5743-5750.
[11] Gonzalez D, Martinez P, Wade R, et al.Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial[J]. J Clin Oncol, 2011, 29(16): 2223-2229.
[12] Petitjean A, Mathe E, Kato S, et al.Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the Iarc TP53 database[J]. Hum Mutat, 2007, 28(6): 622-629.
[13] Li W, Lai B, Yang X, et al.A truncated p53 in human lung cancer cells as a critical determinant of proliferation and invasiveness[J]. Tumour Biol, 2017, 39(6): 1010428317703824.
[14] Cerami E, Gao J, Dogrusoz U, et al.The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data[J]. Cancer Discov, 2012, 2(5): 401-404.
[15] Gao J, Aksoy BA, Dogrusoz U, et al.Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal[J]. Sci Signal, 2013, 6(269): 11-44.
[16] Pignon JP, le Maitre A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 Patients[J]. Radiother Oncol, 2009, 92(1): 4-14.
[17] Ma J, Liu Y, Yang X, et al.Induction chemotherapy in patients with resectable head and neck squamous cell carcinoma: a meta-analysis[J]. World J Surg Oncol, 2013, 11(1):67-73.
[18] Pointreau Y, Atean I, Fayette J, et al.Induction chemotherapy in head and neck cancer: a new paradigm[J].Anticancer Drugs, 2011, 22(7):613-620.
[19] Zhu DW, Liu Y, Yang X, et al.Low Annexin A1 expression predicts benefit from induction chemotherapy in oral cancer patients with moderate or poor pathologic differentiation grade[J]. BMC Cancer, 2013, 13(1):301-310.
[20] Ma J, Tang X, Sun WW, et al.Mutant GDF15 presents a poor prognostic outcome for patients with oral squamous cell carcinoma[J]. Oncotarget, 2016, 7(2): 2113-2122.
[21] Omura G, Ando M, Ebihara Y, et al.The prognostic value of TP53 mutations in hypopharyngeal squamous cell carcinoma[J]. BMC Cancer, 2017, 17(1): 898-907.
[22] Lindenbergh-van der Plas M, Brakenhoff RH, Kuik DJ, et al. Prognostic significance of truncating TP53 mutations in head and neck squamous cell carcinoma[J]. Clin Cancer Res, 2011, 17(11): 3733-3741.
[23] Fernandez-Cuesta L, Oakman C, Falagan-Lotsch P, et al.Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III Trial[J]. Breast Cancer Res, 2012, 14(3): 1-13.
[24] Tandon S, Tudur-Smith C, Riley RD, et al.A systematic review of p53 as a prognostic factor of survival in squamous cell carcinoma of the four main anatomical subsites of the head and neck[J]. Cancer Epidemiol Biomarkers Prev, 2010, 19(2): 574-587.
[25] Eicheler W, Zips D, Dorfler A, et al.Splicing Mutations in TP53 in human squamous cell carcinoma lines influence immunohistochemical detection[J]. J Histochem Cytochem, 2002, 50(2): 197-204.
[26] Scheel A, Bellile E, McHugh JB, et al. Classification of TP53 mutations and HPV predict survival in advanced larynx cancer[J]. Laryngoscope, 2016, 126(9): E292-E299.

TP53截断突变作为局部晚期口腔鳞癌诱导化疗预测性生物标志物的探讨

TP53 truncating mutation as a predictive biomarker for induction chemotherapy in patients with locally advanced oral squamous cell carcinoma

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	赵慧, 舒欣, 张帆, 任伟伟, 刘姣, 朱珠. 基于生物信息学和体外实验筛选头颈鳞癌生物标志物[J]. 中国口腔颌面外科杂志, 2024, 22(4): 329-338.
[2]	郭逸飞, 张永红, 任振虎. 头颈部肉瘤的诊断与治疗现状[J]. 中国口腔颌面外科杂志, 2024, 22(4): 404-408.
[3]	孙晓梅, 段晓峰. 去泛素化酶在口腔鳞癌中的研究进展[J]. 中国口腔颌面外科杂志, 2024, 22(3): 294-299.
[4]	李锦存, 翟堃, 胡晨, 刘絮影, 马兴平, 马坚. 整合WGNCA和PPI网络鉴定口腔鳞状细胞癌的关键基因[J]. 中国口腔颌面外科杂志, 2024, 22(2): 128-136.
[5]	周鑫霞，刘敬浩，甘桂芳，陈福祥. 鞘氨醇-1-磷酸受体4在口腔鳞状细胞癌中的表达及生物学功能[J]. 中国口腔颌面外科杂志, 2024, 22(1): 10-15.
[6]	韩林孜, 周建华, 董磊, 赵璐, 袁荣涛. 肿瘤相关成纤维细胞对口腔鳞状细胞癌生物学行为影响的研究进展[J]. 中国口腔颌面外科杂志, 2024, 22(1): 84-91.
[7]	赵铜超, 梁思源, 周知航, 朱方兴, 琚梧桐, 谈亦然, 刘莹, 钟来平. BMI与局部晚期口腔鳞癌患者预后及诱导化疗效果的相关性研究[J]. 中国口腔颌面外科杂志, 2023, 21(6): 559-565.
[8]	曾慧, 江花香, 胡彦昌, 杨丰瑞, 王军. 基于生物信息学分析筛选舌鳞癌的关键基因[J]. 中国口腔颌面外科杂志, 2023, 21(5): 452-460.
[9]	李贵忠, 李洁莹, 周凯, 孟宇翔, 王可心, 葛胜优, 宋凯, 冯元勇, 陶月琴, 展晓红, 尚伟. 淋巴结外扩展对口腔鳞癌患者TNM分期及生存预后的影响[J]. 中国口腔颌面外科杂志, 2023, 21(4): 377-383.
[10]	热孜万姑丽·亚森, 买热拍提·买明, 李晨曦, 龚忠诚. 牙龈卟啉单胞菌促进口腔鳞状细胞癌进展的作用及机制研究进展[J]. 中国口腔颌面外科杂志, 2023, 21(2): 186-190.
[11]	兰嵘, 阮敏, 韩楠男, 王凤. 左下种植修复后发生植体周围鳞状细胞癌1例报告[J]. 中国口腔颌面外科杂志, 2023, 21(2): 203-205.
[12]	苏姿尚, 崔文丽, 张梦云, 姚志涛. 口腔鳞状细胞癌患者颈部淋巴结特征与预后的关系[J]. 中国口腔颌面外科杂志, 2023, 21(1): 41-48.
[13]	杨慧丽, 王宇帆, 王锋, 沈月洪, 杨宏宇. NLRP1在头颈部鳞癌中的表达及预后意义[J]. 中国口腔颌面外科杂志, 2022, 20(5): 429-436.
[14]	季萍萍, 李莉, 吴奕帆, 侯黎莉. 经皮穴位电刺激防治口腔鳞癌患者诱导化疗后骨髓抑制的效果观察[J]. 中国口腔颌面外科杂志, 2022, 20(5): 455-460.
[15]	赵小妹, 夏荣辉, 钟来平, 朱东旺, 张志愿. Nrf2对口腔鳞癌患者TPF诱导化疗效果的影响[J]. 中国口腔颌面外科杂志, 2022, 20(4): 366-370.